| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-08-2881 |
| P8608 | Fatcat ID | release_agsag5phrjbovkzgflifcu2wai |
| P932 | PMC publication ID | 2871252 |
| P698 | PubMed publication ID | 19318576 |
| P50 | author | Everett E Vokes | Q73567428 |
| Ravi Salgia | Q73567837 | ||
| Tanguy Y Seiwert | Q89776148 | ||
| Mark W. Lingen | Q113027272 | ||
| Rajani Kanteti | Q113027596 | ||
| Ezra E Cohen | Q38641744 | ||
| P2093 | author name string | Leslie Martin | |
| James G Christensen | |||
| Leonardo Faoro | |||
| Soheil Yala | |||
| Soundararajan Krishnaswamy | |||
| Ramasamy Jagadeeswaran | |||
| Andres Klein-Szanto | |||
| Vidya Nallasura | |||
| Mohamed El Dinali | |||
| Varalakshmi Janamanchi | |||
| P2860 | cites work | Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 |
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. | Q54017063 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression | Q59565588 | ||
| Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 | ||
| Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases | Q73911408 | ||
| Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance | Q74287365 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 | ||
| Targeting the c-Met signaling pathway in cancer | Q28246393 | ||
| The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants | Q28254690 | ||
| Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion | Q28263339 | ||
| MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival | Q28282398 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples | Q33950256 | ||
| A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase | Q34263863 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues | Q35575126 | ||
| Signaling networks assembled by oncogenic EGFR and c-Met | Q36392991 | ||
| Activating mutations for the met tyrosine kinase receptor in human cancer | Q36595980 | ||
| The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis | Q36601812 | ||
| Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. | Q36882696 | ||
| The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer | Q36899915 | ||
| Expression and mutational analysis of MET in human solid cancers | Q36975055 | ||
| Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx | Q38450015 | ||
| Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma | Q38512195 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts | Q40144642 | ||
| Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma | Q40333091 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. | Q40514504 | ||
| c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions | Q40626106 | ||
| SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. | Q40749632 | ||
| Scatter factor expression and regulation in human glial tumors | Q41184022 | ||
| MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. | Q43827034 | ||
| Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor | Q45143177 | ||
| Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. | Q46813416 | ||
| Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck | Q47257497 | ||
| c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases | Q47349579 | ||
| Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. | Q47576232 | ||
| Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. | Q47828818 | ||
| Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. | Q53479014 | ||
| Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. | Q53875696 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | head and neck squamous cell carcinoma | Q18348812 |
| P304 | page(s) | 3021-3031 | |
| P577 | publication date | 2009-03-24 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | |
| P478 | volume | 69 |
| Q89776150 | A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma |
| Q33541323 | A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes |
| Q86035602 | A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head |
| Q37022410 | Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma |
| Q47303095 | Activated HGF-c-Met Axis in Head and Neck Cancer |
| Q36005545 | Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer |
| Q38118934 | Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance |
| Q61814976 | Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer |
| Q38896144 | Biological predictors of radiosensitivity in head and neck squamous cell carcinoma |
| Q28085247 | Biology of MET: a double life between normal tissue repair and tumor progression |
| Q59611470 | Biomarker driven treatment of head and neck squamous cell cancer |
| Q35023515 | Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q38476034 | Cancer stem cells: a potential target for cancer therapy |
| Q39838383 | Candidate Biomarkers for HPV-Negative Head and Neck Cancer Identified via Gene Expression Barcode Analysis |
| Q89823977 | Characterizations of Gene Alterations in Melanoma Patients from Chinese Population |
| Q92445608 | Circadian (De)regulation in Head and Neck Squamous Cell Carcinoma |
| Q33695197 | Clinical update on cancer: molecular oncology of head and neck cancer |
| Q49414583 | Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review |
| Q34156955 | Comparative analysis of algorithms for integration of copy number and expression data |
| Q39305660 | Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review. |
| Q53187961 | Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma. |
| Q37976623 | Current treatment options for metastatic head and neck cancer |
| Q35206363 | DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer |
| Q36536575 | DSG3 as a biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using nanostructured immunoarrays |
| Q28743359 | Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay |
| Q35487148 | Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study |
| Q59358375 | Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma |
| Q38770450 | Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups. |
| Q35110418 | Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells |
| Q38771636 | Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. |
| Q38734640 | Effects and Mechanism of Imatinib in Inhibiting Colon Cancer Cell Proliferation |
| Q38268896 | Emerging biomarkers in head and neck cancer in the era of genomics. |
| Q45874449 | Emerging drugs for head and neck cancer |
| Q36090422 | Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR |
| Q39144705 | Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models |
| Q37632913 | Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis |
| Q39482081 | Expression and clinical relevance of MET and ALK in Ewing sarcomas. |
| Q38380044 | Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma |
| Q36518737 | Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma |
| Q43083986 | Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition |
| Q39524625 | Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells |
| Q84396290 | Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma |
| Q59465394 | Genomically personalized therapy in head and neck cancer |
| Q38883827 | HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. |
| Q37060950 | HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma |
| Q39389369 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. |
| Q92531037 | Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients |
| Q33607965 | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment |
| Q49386899 | High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma |
| Q39566894 | Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation |
| Q38164587 | Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes. |
| Q53689233 | Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. |
| Q39539278 | Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers |
| Q33901521 | Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 |
| Q42837140 | Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer |
| Q54957173 | Invasion-Related Factors as Potential Diagnostic and Therapeutic Targets in Oral Squamous Cell Carcinoma-A Review. |
| Q37736496 | Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma |
| Q61852873 | Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors |
| Q37490555 | MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma |
| Q39643704 | MET mutations in cancers of unknown primary origin (CUPs). |
| Q33756836 | MET receptor tyrosine kinase |
| Q96230891 | MET-dependent solid tumours - molecular diagnosis and targeted therapy |
| Q38430194 | MET: a new promising biomarker in non-small-cell lung carcinoma |
| Q52607160 | Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. |
| Q34613189 | Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis |
| Q38821826 | Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. |
| Q38087239 | Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications |
| Q33365218 | Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma |
| Q35582737 | Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle |
| Q37806926 | New advances in targeted therapies for squamous cell carcinoma of the head and neck |
| Q64238086 | Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma |
| Q30441193 | Novel insight into mutational landscape of head and neck squamous cell carcinoma |
| Q38118439 | Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition |
| Q38221292 | Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation |
| Q28540413 | Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma |
| Q58617725 | Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation |
| Q33717395 | PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models |
| Q34273411 | Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics |
| Q33918113 | Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma |
| Q36203560 | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial |
| Q36660533 | Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. |
| Q36729516 | Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial |
| Q38711090 | Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells |
| Q39770991 | Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer |
| Q39616531 | Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihy |
| Q36149312 | Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. |
| Q54515534 | Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. |
| Q35836427 | Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer |
| Q33725229 | Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. |
| Q26852215 | Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer |
| Q39466612 | Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer |
| Q36446461 | Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma |
| Q35102025 | Receptor-tyrosine-kinase-targeted therapies for head and neck cancer |
| Q41814094 | Regulation of cell migration via the EGFR signaling pathway in oral squamous cell carcinoma cells |
| Q34463471 | Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 |
| Q38167258 | Role of met axis in head and neck cancer |
| Q42735478 | Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. |
| Q34094632 | Small molecule c-Met kinase inhibitors: a review of recent patents |
| Q34160540 | Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee |
| Q38756969 | Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib |
| Q36406993 | Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma |
| Q34627751 | Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice |
| Q24606259 | Targeting the hepatocyte growth factor-cMET axis in cancer therapy |
| Q36536993 | The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer |
| Q92661565 | The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma |
| Q55065289 | The absolute bioavailability investigation of LS177 in rats using ultra-performance liquid chromatography-tandem mass spectrometry. |
| Q30534479 | The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation |
| Q37821229 | The molecular biology of head and neck cancer |
| Q36659339 | The molecular pathogenesis of head and neck squamous cell carcinoma |
| Q35146937 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy |
| Q34256064 | Tongue carcinoma infrequently harbor common actionable genetic alterations |
| Q28074691 | Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma |
| Q37059865 | Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck |
| Q26748581 | Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? |
| Q33823715 | Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells |
| Q37962905 | c-MET as a potential therapeutic target and biomarker in cancer |
| Q26775483 | c-Met as a Target for Personalized Therapy |
| Q35650167 | c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target |
| Q34883707 | c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase |
Search more.